BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/1/2021 12:36:04 PM | Browse: 507 | Download: 1341
 |
Received |
|
2020-10-09 09:17 |
|
Peer-Review Started |
|
2020-10-09 09:17 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-11-03 00:39 |
|
Revised |
|
2020-11-09 07:59 |
|
Second Decision |
|
2020-11-16 11:29 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-11-21 05:47 |
|
Articles in Press |
|
2020-11-21 05:47 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-11-26 23:01 |
|
Typeset the Manuscript |
|
2020-12-28 15:12 |
|
Publish the Manuscript Online |
|
2021-01-01 12:36 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ci Tian, Nan Li, Yi Bai, Han Xiao, Shu Li, Qing-Gang Ge, Ning Shen and Qing-Bian Ma |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qing-Bian Ma, MD, Associate Professor, Chairman, Chief Physician, Department of Emergency Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. maqingbian@bjmu.edu.cn |
| Key Words |
COVID-19; Hypertension; Angiotensin converting enzymes inhibitors; Angiotensin receptor blockers; Angiotensin-converting enzyme-2; Prognosis |
| Core Tip |
Recent research revealed that the ingestion of angiotensin converting enzymes inhibitors or angiotensin receptor blockers (ACEIs/ARBs) had no significant harm on coronavirus disease 2019 (COVID-19) patients complicated with hypertension. However, the impact of discontinue using ACEIs/ARBs in those patients was still unclearly. In the present study, we retrospectively collected the clinical data of patients with both COVID-19 and hypertension, and to explore whether any difference in disease outcomes occurred between patients who discontinued using ACEIs/ARBs and those who continued using other anti-hypertensive drugs. |
| Publish Date |
2021-01-01 12:36 |
| Citation |
Tian C, Li N, Bai Y, Xiao H, Li S, Ge QG, Shen N, Ma QB. Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension. World J Clin Cases 2021; 9(1): 47-60 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i1/47.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i1.47 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
